A
Andrew Collins
Researcher at University of Oslo
Publications - 733
Citations - 44066
Andrew Collins is an academic researcher from University of Oslo. The author has contributed to research in topics: Comet assay & DNA damage. The author has an hindex of 100, co-authored 684 publications receiving 40634 citations. Previous affiliations of Andrew Collins include Norwegian University of Life Sciences & Pontifical Xavierian University.
Papers
More filters
Journal ArticleDOI
Deletion Size Influences Clinical Outcome In Patients with Chronic Lymphocytic Leukemia; 13q Deletion Anatomy, Cooperating Lesions and Cancer Pathogenesis
Helen Parker,Matthew Jj Rose-Zerilli,Anton Parker,Tracy Chaplin,Anne Gardiner,Michael J. Griffiths,Andrew Collins,Bryan D. Young,David Oscier,Jonathan C. Strefford +9 more
TL;DR: An updated analysis of the Affymetrix SNP 6.0 genomic profiling study of 224 patients confirms the association between 13q deletion size and disease progression, and proposes a novel gene cluster centromeric to the 13q MDR.
Journal Article
Human Lens Epithelium in Cataract: Qualitative and Quantitative Evaluation of DNA Damage, Apoptosis and Evaluation of a System for Intervention Assays
Oyvind Ringen,A. Oscoz,Kristiane Haug,Mc Moe,Charlotta Zetterström,Andrew Collins,Bjørn Nicolaissen +6 more
Reference EntryDOI
Association Analysis (Linkage Disequilibrium Analysis)
Journal ArticleDOI
Mutations In XPO1, POT1, BIRC3 and FBXW7 collectively Predict Poor Outcome At Diagnosis In CLL and MBL Independent From The SF3B1 and NOTCH1 Status
Mathew J Rose-Zerilli,Jade Forster,Mathew Parry,Anton Parker,Anne Gardiner,Zadie A. Davies,Andrew J. Steele,Helen Parker,Andrew Collins,Nicholas C.P. Cross,David Oscier,Jonathan C. Strefford +11 more
TL;DR: This study suggests that identifying mutations in genes other than NOTCH1 and SF3B1 may have utility in the clinical management of MBL and CLL as they predict for progressive disease, reduced survival and reduced survival.